Treatment of Migraine Attacks with A Long-Acting Somatostatin Analogue (Octreotide, SMS 201-995)

Long-acting somatostatin analogue (SMS 201-995) inhibits serotonin, bradykinin, prostaglandins, substance P, and vasoactive intestinal peptide, which may be involved in migraine. We therefore decided to test the efficacy of SMS 201-995 in relieving the pain of acute migraine attacks. Headache relief was defined as a reduction in severity from grade 3 or 2 (severe or moderate) to 1 or 0 (mild or none). Patients experiencing migraine attacks were evaluated clinically. A double-blind parallel group trial was performed in which patients randomly received either a subcutaneous injection of placebo (saline) or SMS 201-995 (100 μg). SMS 201-995 was significantly more effective than placebo in reducing headache grade at 2 h (1.5 0.6 vs 2.2 0.7; p < 0.01), 4 h (1.6 ± 0.6 vs 2.1 ± 0.8; p < 0.05) and 6 h (0.8 ± 0.9 vs 2.1 ± 0.8; p < 0.001) after the initiation of treatment. By 6 h, apparent headache relief (reduction in severity from grade 3 or 2 to 1 or 0) was experienced in 76.5% of SMS 201-995 treated patients and 25% of the placebo-treated group. Headache relief was significantly better in patients taking SMS 201-995 (p < 0.02). Furthermore, none of the patients became pain-free (headache grade 0) on placebo, while significantly more patients (47%) were pain-free on SMS 201-995 at 6 h (p < 0.01). Headache improvement started significantly earlier in those patients treated with SMS 201-995 than with placebo. SMS 201-995 significantly improves the pain of migraine attacks, 2 h after the beginning of treatment. Additionally, we observed no side effects of SMS 201-995. We therefore conclude that a single dose of 100 μg given subcutaneously is an effective and well-tolerated agent for the treatment of migraine attacks.

[1]  C. Bennett-Clarke,et al.  Distribution of somatostatin in the rat brain: Telencephalon and diencephalon , 1980, Brain Research.

[2]  W. Banks,et al.  Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. Debas,et al.  Somatostatin analogue therapy in functioning neuroendocrine gut tumors. , 1993, Digestion.

[4]  P. Geppetti,et al.  Substance P and enkephalins: a creditable tandem in the pathophysiology of cluster headache and migraine. , 1986, Advances in experimental medicine and biology.

[5]  L. Kvols,et al.  Treatment of the Malignant Carcinoid Syndrome , 1987 .

[6]  P. Curtis‐Prior.  Prostaglandins : biology and chemistry of prostaglandins and related eicosanoids , 1988 .

[7]  H. Cramer,et al.  Permeability of epidural somatostatin and morphine into the intrathecal space of dogs , 1986, Regulatory Peptides.

[8]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[9]  G. Tolis.  Long-term management of acromegaly with sandostatin. , 1988, Hormone research.

[10]  R. Penn,et al.  Distribution of a somatostatin analog after continuous intraventricular administration. , 1989, Neurosurgery.

[11]  H. Mekhjian,et al.  Octreotide inhibits increases in short-circuit current induced in rat colon by VIP, substance P, serotonin and aminophylline , 1990, Regulatory Peptides.

[12]  F. Sicuteri.  Vasoneuroactive Substances and their Implication in Vascular Pain , 1967 .

[13]  R. Meier,et al.  Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. , 1993, Digestion.

[14]  M. Adler,et al.  Differential release of substance P and somatostatin in the rat spinal cord in response to noxious cold and heat: effect of dynorphin A(1-17). , 1990, NIDA research monograph.

[15]  H. Cox,et al.  The antisecretory effects of somatostatin and analogues in rat descending colon mucosa. , 1990, European journal of pharmacology.

[16]  B. Lembcke,et al.  Short-Term Administration of the Somatostatin Analogue SMS 201-995 in Patients with Carcinoid Tumours , 1986 .

[17]  J. Lance,et al.  A Placebo-Controlled Study of Intranasal Sumatriptan for the Acute Treatment of Migraine , 1991 .

[18]  Giuseppe Orefice,et al.  Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study , 1988, Cephalalgia : an international journal of headache.